Home › Compare › ASLRF vs ABBV
ASLRF yields 117647.06% · ABBV yields 3.06%● Live data
📍 ASLRF pulled ahead of the other in Year 1
Combined, ASLRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ASLRF + ABBV for your $10,000?
Alien Metals Ltd, together with its subsidiaries, engages in the acquisition and development of mineral resource assets. The company explores for copper, zinc, lead, silver, gold, iron ore, and precious metal deposits. The company holds a 100% interest in Vivash Gorge Iron Ore Project located in the Pilbara region of Western Australia. It also holds interest in the Donovan 2 project, the Los Campos project, and the San Celso project located in Mexico; the Elizabeth Hill project, the Munni Munni North project, the Munni Munni PGE project, and the Brockman and Hancock iron project situated in Western Australia; and the Citronen project located in Greenland. The company was formerly known as Arian Silver Corporation and changed its name to Alien Metals Limited in October 2018. Alien Metals Ltd was founded in 2006 and is headquartered in London, the United Kingdom.
Full ASLRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.